🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Kicking off the PH content The ISHLT with an in depth session on Coming together: improving survival in PAH! #ISHLT2024

Sophia Airhart MD discusses risk assessment in adults with PAH: achieving low risk status ASAP is key to improved 1 year survival, utilization of risk assessment remains low.

Allen Everett reviews the development and implementation of a risk assessment model in pediatric PAH patients in PPHNet, with validation against Dutch and Spanish registries.

Tor Clemmensen takes us through CAV pathogenesis: Step 1 endothelial injury and dysfunction (relating to donor, recipient, and surgical factors); Step 2 smooth muscle cell proliferation (CMV infection, DSAs).. much yet to be known

Maxime Tremblay-Gravel notes biomarkers in CAV not currently guideline-recommended, but several metabolic (TChol, TGs), inflammatory (CRP), proteomic, circulating microRNAs, immunologic (Class II DSAs, GEP), injury markers (BNP, troponin, ddcfDNA) all have been associated with CAV

Lindsey Aurora outlines txt and prevention: aspirin (RCT AERIAL TBD), early PSI/mTOR, LDL control (aim <100 or <50 if CAV present). PCSK9i safe & effective post-OHT. Redo OHT for grade 3 more advantageous if LV dysfunction present. In the future: Belatecept? tocilizumab? SGLT2i?

Guillaume Coutance discusses that the natural history of CAV has 4 major trajectories (none, mild/late, severe/late, and severe/early). Invasive biomarkers and predictive models will one day help us define patients’ trajectories

Hascoet Sébastien (Hôpital Marie-Lannelongue, GHPSJ) PRO for transcutaneous shunts,🎈septostomy outcomes improving, ⬇️RAP, ⬆️CI, helps symptoms, patency better w/ atrial flow regulators. Re: Potts TC options game-changing, easy when PDA present, still feasible w/o PDA & new devices in development

David Morales (Cincinnati Children's) CON for transcutaneous shunts. Data for atrial septostomy old and limited in kids. Surgical Potts pts come off IV prostanoids, better outcomes than lung txplt. Registries of TC-Potts a/w worse outcomes, complicates/limits eventual txplt

Great session on early career and trainee clinical case dilemmas, loved the pairing of trainee clinical case + expert discussant. A little bit of everything 🫀🫁 ⚙️ #HeartTransplant #LungTransplant #MCS #LVAD #PVD #PAH

Anas Jawaid (UT Southwestern Medical Center) presents on 41W w/ deafness who underwent HM3 w/ use of haptic devices (bed shaker, pager, smartwatch) to ensure detection of LVAD alarms. Kathleen Grady (Northwestern Medicine) emphasizes need to optimize access, safety, personalization in LVAD

Rise and shine! ☀️ Early birds at #ISHLT2024 caught the worm with a groundbreaking session on CTEPH. #PVD #CTEPH #SunriseScience

Marc de Perrot on interventions. PEA for segmental dz, but BPA+meds beneficial. RACE & MR BPA RCTs (BPA vs rio in non-surgical)– BPA w/ better hemodynamics but adverse events. PEA risk driven by RV failure, VA-ECMO to bridge to recovery after PEA beneficial

Isabelle Opitz on f/u. Persistent PH after PEA common (25%), PVR>5 a/w worse survival. Re-assess at 3-6 mo, RHC needed. Target FC I-II & normalize resting hemodynamics. Need for standardized f/u schemes. Echo/ NTproBNP (>300) at 6mo may help (some missed cases), early data on microRNA

🚀 Dive into the primary data with 'What’s New in Pulmonary Vascular Disease' - the latest updates from registries and clinical trials moderated by MarcSimonMD Dr Mardi Gomberg #ISHLT2024 #PAH #PVD

Raymond Benza MD's analysis of TORREY compared risk tools (REVEAL 2.0 & Lite 2, COMPERA 2.0, Non-invasive French), showed seralutinib favorably shifted risk scores at 24 wks. COMPERA 2.0 significantly improved (OR 9.32, p<0.05), REVEAL 2.0 and French w/ trend

In a post-hoc analysis of STELLAR and PULSAR, Dr Mardi Gomberg stratified pts by cardiac index (cutoff of 2 or 2.5) & sotatercept improved 6MWD, PVR, NTproBNP, echo parameters (RVEF, TAPSE/SPAP), WHO-FC in all CI subgroups. Similar safety across CIs

🍼 405. CardioNerds Case Report: Like Mother, Like Son 💗Explore a case of peripartum cardiomyopathy & infantile HCM unifying a diagnosis💗 Feat: Drs. Tabitha Moe MD, FACC Harrison VanDolah, Sri Nayak & Donny Mattia, Pooja Prasad, MD ‼️ Mayo Clinic AZ CV Fellows Link below👇👇👇

🔗uscjournal.com/articles/remot… Pooja Prasad, MD Cali Clark, DO MBA Ankit Bhatia, MD @

🔬 Mentorship Pairing #2, sponsored by BridgeBio Pharma, winners announced! Congratulations to Pooja Prasad, MD & Hanna Gaggin who will delve into critical aspects of ATTR-CM research through their collaborative project over the next 12 months. #WomenAsOneAwards #WIC